Theratechnologies Inc. (TSX:TH)

Market Cap	207.37M
Revenue (ttm)	116.07M
Net Income (ttm)	-12.60M
Shares Out	45.98M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	82.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,975
Average Volume	26,771
Open	4.500
Previous Close	4.510
Day's Range	4.480 - 4.510
52-Week Range	1.590 - 4.540
Beta	0.83
RSI	65.99
Earnings Date	Oct 8, 2025

About Theratechnologies

Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its product pipeline includes tesamorelin...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 103
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: TH

Financial Performance

In 2024, Theratechnologies's revenue was $85.87 million, an increase of 5.02% compared to the previous year's $81.76 million. Losses were -$8.31 million, -65.33% less than in 2023.

Financial numbers in USD